Claims
- 1. A peptide comprising an amino acid sequence selected from the group consisting of CAFRQVC.
- 2. A polypeptide conjugate comprising the peptide of claim 1 linked to a carrier.
- 3. An antigenic composition comprising the peptide of claim 1.
- 4. The antigenic composition of claim 3, wherein the peptide specifically binds to an anti-retroviral antibody selected from the group consisting of anti-HIV-1 and anti-HIV-2 antibodies.
- 5. An antigenic composition comprising the polypeptide conjugate of claim 2 and a pharmaceutically acceptable vehicle.
- 6. An in vitro method of detecting antibodies selectively binding to a retrovirus selected from the group consisting of HIV-1 and HIV-2 in a biological sample, comprisingcontacting a biological sample suspected of comprising an antibody having specificity for a retrovirus selected from the group consisting of HIV-1 and HIV-2 with the peptide of claim 1, a conjugate thereof with a carrier, or a mixture thereof, and detecting any peptide-antibody or conjugate-antibody complexes formed.
- 7. The in vitro method of claim 6, wherein the detection of the peptide-antibody or conjugate-antibody complexes formed is carried out by an immunoenzymatic, immunofluorescence, radioimmunological, or radioimmunoprecipitation assay.
- 8. A kit for the in vitro detection of antibodies selectively binding to a retrovirus selected from the group consisting of the HIV-1 and HIV-2 viruses comprising in separate containersa composition comprising the peptide of claim 1, a conjugate thereof with a carrier, or a mixture thereof; at least one first reagent for the preparation of a medium suitable for carrying out an immunological reaction with the composition; at least one further reagent for the detection of antigen-antibody complexes formed during an immunological reaction; and at least one reference sample comprising a known quantity of antibodies capable of specifically binding to the composition but free of any other antibodies.
- 9. The peptide of claim 1, wherein the peptide has 40 or less amino acid residues.
- 10. A polypeptide conjugate comprising the peptide of claim 9 being linked to a carrier.
- 11. An antigenic composition comprising the peptide of claim 9 or mixtures thereof.
- 12. The antigenic composition of claim 11, wherein the peptide specifically binds to an anti-retroviral antibody selected from the group consisting of anti-HIV-1 and anti-HIV-2 antibodies.
- 13. An antigenic composition comprising the polypeptide conjugate of claim 12 and a pharmaceutically acceptable vehicle.
- 14. An in vitro method of detecting antibodies selectively binding to a retrovirus selected from the group consisting of HIV-1 and HIV-2 in a biological sample, comprisingcontacting a biological sample suspected of comprising an antibody having specificity for a retrovirus selected from the group consisting of HIV-1 and HIV-2 with the peptide of claim 9, a conjugate thereof with a carrier, or a mixture thereof, and detecting any peptide-antibody or conjugate-antibody complexes formed.
- 15. The in vitro method of claim 14, wherein the detection of the peptide-antibody or conjugate-antibody complexes formed is carried out by an immunoenzymatic, immunofluorescence, radioimmunological, or radioimmunoprecipitation assay.
- 16. A kit for the in vitro detection of antibodies selectively binding to a retrovirus selected from the group consisting of the HIV-1 and HIV-2 viruses comprising in separate containersa composition comprising the peptide of claim 9, a conjugate thereof with a carrier, or a mixture thereof; at least one first reagent for the preparation of a medium suitable for carrying out an immunological reaction with the composition; at least one further reagent for the detection of antigen-antibody complexes formed during an immunological reaction; and at least one reference sample comprising a known quantity of antibodies capable of specifically binding to the composition but free of any other antibodies.
Priority Claims (5)
Number |
Date |
Country |
Kind |
86 00911 |
Jan 1986 |
FR |
|
86 01635 |
Feb 1986 |
FR |
|
86 01985 |
Feb 1986 |
FR |
|
86 03881 |
Mar 1986 |
FR |
|
86 04215 |
Mar 1986 |
FR |
|
Parent Case Info
This is a continuation of application Ser. No. 08/774,736, filed Jan. 2, 1997 now U.S. Pat. No. 6,261,762 which is a division of 07/810,908, filed Dec. 20, 1991, which is a division of 07/752,368, filed Sep. 3, 1991 now abandoned, which is a division of 07/013,477, filed Feb. 11, 1987 now U.S. Pat. No. 5,079,342, which is a division of 07/003,764, filed Jan. 16, 1981 now U.S. Pat. No. 5,051,496, which is a CIP of 06/933,184, filed Nov. 21, 1986 now abandoned, which is a CIP of 06/916,080, filed Oct. 6, 1986 now abandoned, which is a CIP of 06/835,228, filed Mar. 3, 1986 now U.S. Pat. No. 4,839,288, which is a CIP based on FR 86 00911, filed on Jan. 22, 1986, based on FR 86 01635, filed on Feb. 6, 1986, based on FR 86 01985, filed Feb. 13, 1986, based on FR 86 03881, filed on Mar. 18, 1986, based on FR 86 04215, filed on Mar. 24 1986, incorporated herein by reference.
US Referenced Citations (7)
Number |
Name |
Date |
Kind |
4629783 |
Cosand |
Dec 1986 |
A |
4839288 |
Montagnier et al. |
Jun 1989 |
A |
5079342 |
Alizon et al. |
Jan 1992 |
A |
5480966 |
Sommé et al. |
Jan 1996 |
A |
5670309 |
Norrby et al. |
Sep 1997 |
A |
5721095 |
Chan et al. |
Feb 1998 |
A |
6261762 |
Alizon et al. |
Jul 2001 |
B1 |
Foreign Referenced Citations (2)
Number |
Date |
Country |
0 316 695 |
Mar 1993 |
EP |
WO 8504897 |
Nov 1985 |
WO |
Non-Patent Literature Citations (18)
Entry |
Allan et al., “Major Glycoprotein Antigens That Induce Antibodies in AIDS Patients Are Encoded by HTVL-III,” Science 228:1091-94 (1985). |
Barin et al., “Serological Evidnece For Virus Related to Simian T-lymphotropic Retrovirus III in Residents of West Africa,” The Lancet 2:1387-1389 (1985). |
Chang et al., “Detection of Antibodies to Human T-Cell Lymphotropic Virus-III (HTLV-III) with an Immunoassay Employing a Recombinant Escherichia coli-Derived viral Antigenic Peptide,” bio/Technology 3:905-909 (1985). |
Clavel et al., “Isolation of a New Human Retrovirus from West African Patients with AIDS,” Science 233:343-346 (1986). |
Clavel et al., “LAV Type II: A Second Retrovirus Associated with AIDS in West Africa,” C.R. Acad. Sci. Paris, Series III 302:485-488 (1986). |
Clavel et al., “Molecular cloning and polymorphism of the human immunodeficiency virus type 2,” Nature 324:691-695 (1986). |
Daniel et al., “Isolation of T-Cell Tropic HTLV-III-like Retrovirus from Macaques,” Science 228:1201-1204 (1985). |
Damell et al., “The Molecules in Cells: Proteins,” Molecular Cell Biology, pp. 53-57 (1986). |
Fields et al., “Human Immunodeficiency Viruses and Their Replication,” Virology 2:1913-16 (1996 3rd ed). |
Gallo et al., “HIV/HTLV gene nomenclature,” Nature 333:504 (1988). |
Gao et al., “Genetic Diversity of Human Immunodeficiency Virus Type 2: Evidence for Distinct Sequence Subtypes with Differences in Virus Biology,” J. Virol. 68(11):7433-7447 (1994). |
Goodenow et al., “HIV-1 Isolates Are Rapidly Evolving Quasispecies: Evidence for Viral Mixtures and Preferred Nucleotides Substitutions,” J. Acquir. Immun. Defic. Syndr. 2:344-352 (1989). |
Kanki et al., “Isolation of T-lymphotropic Retrovirus Related to HTLV-III/LAV from Wild-Caught African Green Monkeys,” Science 230:951-954 (1985). |
Kanki et al., “Serologic Identification and Characterization of a Macaque T-lymphotropic Retrovirus Closely Related to HTLV-III,” Science 228:1199-1201 (1985). |
Klatzmann et al., “T-lymphocyte T4 Molecule Behaves As The Receptor for Human Retrovirus LAV,” Nature 312:767-768 (1984). |
Laurence, J., “Editorial Update: HIV-1 Gene Nomenclature,” AIDS Res. Hum. Retroviruses 4:vii-viii (1988). |
Mitsuya et al., “Protection of T Cells Against Infectivity and Cytopathic Effect of HTLV-III In Vitro,” Retroviruses in Human Lymphoma/Leukemia, Proceedings of the 15th International Symposium of The Princess Takamatsu Cancer Research Fund, Tokyo, 1984, 277-288 (1985). |
Sandstrom et al., “Antiviral Therapy in AIDS Clinical Pharmacological Properties and Therapeutic Experience to Date,” Drugs 34:372-390 (1987). |
Continuations (1)
|
Number |
Date |
Country |
Parent |
08/774736 |
Jan 1997 |
US |
Child |
09/862029 |
|
US |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
06/933184 |
Nov 1986 |
US |
Child |
07/003764 |
|
US |
Parent |
06/916080 |
Oct 1986 |
US |
Child |
06/933184 |
|
US |
Parent |
06/835228 |
Mar 1986 |
US |
Child |
06/916080 |
|
US |